RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1

Area of Science:

• Molecular Biology
• Genetics
• Neurology

Background:

• Myotonic dystrophy type 1 (DM1) is an RNA-dominant disorder.
• Pathology involves expanded CUG repeats in transcripts, leading to RNA foci.
• Nuclear depletion of MBNL1 and stabilized CELF1 cause splicing dysregulation and neuromuscular issues.

Purpose of the Study:

• To investigate antisense oligonucleotides (ASOs) as a therapeutic strategy for DM1.
• To design and evaluate chimeric ASOs (gapmers) for targeting pathogenic CUG-repeat transcripts.

Main Methods:

• Design of chimeric ASOs (gapmers) with modified nucleic acid residues.
• Utilizing RNase H-mediated degradation to target CUG-repeat transcripts.
• Assessment of gapmer efficacy in cell culture and DM1 mouse models for RNA foci disruption.

Main Results:

• Gapmers selectively reduced expanded CUG-repeat transcripts.
• Disruption of nuclear RNA foci was observed in both cell culture and mouse models.
• Combination therapy with morpholino ASOs showed potential for enhanced knockdown.

Conclusions:

• ASOs, specifically gapmers, represent a promising therapeutic strategy for DM1 by targeting toxic RNA.
• This approach effectively reduces RNA foci and offers potential for improved splicing regulation.
• Further optimization is needed for systemic delivery, but this provides an alternative therapeutic avenue.